Nuoncology Labs Inc
OTC:NLAB
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
US |
N
|
Nuoncology Labs Inc
OTC:NLAB
|
29.3B USD | -1 004 063.9 | |
CA |
A
|
Advance Lithium Corp
XTSX:AALI
|
486.5B CAD | -749 832 | |
US |
G
|
Gould Investors LP
OTC:GDVTZ
|
334.2B USD | 0 | |
US |
C
|
Carson Energy Development Corp
OTC:CDVM
|
270.6B USD | -77 926.9 | |
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
78.8B Zac | 0 | |
US |
Music Licensing Inc
OTC:SONG
|
64.3B USD | 1 396.6 | ||
ID |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
902.9T IDR | 36.4 | ||
US |
Liberty Bancshares Inc
OTC:LBSI
|
55.5B USD | 0 | ||
US |
Ergo Science Corp
OTC:ERGN
|
55.2B USD | -10 816.3 | ||
US |
H
|
HK Graphene Technology Corp
OTC:HKGT
|
53.9B USD | -34 818.3 | |
US |
G
|
GE Vernova LLC
NYSE:GEV
|
48.2B USD | 0 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.